Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineZacks Investment Research • 04/27/23
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.GlobeNewsWire • 04/26/23
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVBBusiness Wire • 03/29/23
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVBPRNewsWire • 03/14/23
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with SanofiPRNewsWire • 03/13/23
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealProactive Investors • 03/13/23
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to ShareholdersBusiness Wire • 03/13/23
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallPRNewsWire • 03/13/23
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)GlobeNewsWire • 03/13/23
Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 03/09/23
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023PRNewsWire • 02/23/23
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A WorrySeeking Alpha • 02/22/23
Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?Zacks Investment Research • 02/13/23